DANA-FARBER CANCER INSTITUTE

Yale’s Department of Biomedical Informatics and Data Science (BIDS) welcomes Haoyu Cheng, Anran Li, Andrew Loza, Julia Wolleb, Weipeng Zhou, João Cardoso, Catherine Barabas, Gui Yang, Mukund Aravapalli, Jennifer Arango, Ahmed Abdelhady, Winnie Ng, Vincent Zhang, and Atharva Sapre, each contributing unique expertise in genomics, AI, software engineering, and healthcare informatics.

Nomic and PICI collaborate to profile ~3000 blood samples from RADIOHEAD study using nELISA™ to understand immunotherapy responses, aiming to improve patient care through precision medicine.

Maria De Santis discusses TAR-200's high CR rate in BCG-unresponsive NMIBC, AMBASSADOR's extended DFS benefits with adjuvant pembrolizumab, and VOLGA's potential of ctDNA clearance as a treatment tailoring tool in bladder cancer.

A 10-year follow-up of the CheckMate 067 trial showed that 50% of metastatic melanoma patients treated with nivolumab and ipilimumab experienced cancer-free survival of 10 years or longer, with no new safety signals identified.

Cabozantinib significantly improved progression-free survival in advanced pancreatic and extra-pancreatic neuroendocrine tumors, potentially becoming the new standard of care, according to the Phase III CABINET trial results.

Cabozantinib significantly improves progression-free survival in patients with previously treated pancreatic and extrapancreatic neuroendocrine tumors, according to the CABINET trial. The study, presented at ESMO 2024 and published in NEJM, showed median progression-free survival of 13.8 months vs 4.4 months for pancreatic tumors and 8.4 months vs 3.9 months for extrapancreatic tumors. The FDA accepted a supplemental NDA for cabozantinib in August 2024.

Lung cancer experts discuss practice-changing research and new agents at the 2024 IASLC World Conference, highlighting Ivonescimab's potential in NSCLC, rethinking immunotherapy approaches, emerging biomarker-driven therapies, promising HER2 TKIs, ADC developments in SCLC, novel drug delivery platforms, and patient-centered care.

Toni K. Choueiri, MD, discusses the TiNivo-2 study findings on tivozanib–nivolumab vs tivozanib monotherapy in RCC patients post-ICI, presented at the 2024 ESMO Annual Congress in Barcelona.

FDA approves Kisqali, a CDK4/6 inhibitor by Novartis, for early-stage breast cancer, expanding its use to include stage 2 and 3 HR positive, HER2 negative patients without positive lymph nodes. Kisqali, combined with hormone therapy, aims to reduce recurrence risk by 28.5% over endocrine therapy alone, as shown in the NATALEE trial. Common side effects include low white blood cell counts and joint pain, and it is administered for three years post-surgery.

Enhertu (trastuzumab deruxtecan) demonstrated significant overall and intracranial clinical activity, including prolonged PFS, in HER2-positive mBC patients with brain metastases in the DESTINY-Breast12 trial. The findings support Enhertu's potential as a second-line treatment, with a 12-month PFS rate of 61.6% and CNS PFS rate of 58.9% among patients with brain metastases.